Erotides ST, Costa-Silva M, Correa CG, Denardin G, Ayres AML, Pacheco HCMS, Muraro-Wildner L, Luiza-Bazzo M, González-Chica DA, Dantas-Correa EB, Narciso-Schiavon JL, de Lucca SL

Idioma: Ingles.
Referencias bibliográficas: 67
Paginas: 286-299
Archivo PDF: 303.28 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Juakiem W, Torres DM, Harrison SA. Nutrition in cirrhosis and chronic liver disease. Clin Liver Dis 2014; 18: 179-90.

2. DiSpirito JR, Mathis D. Immunological contributions to adipose tissue homeostasis. Semin Immunol 2015; 27: 315-21.

3. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6: 87-102.

4. Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci 2004; 61: 2485-96.

5. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-47.

6. Falcao-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenco AP, Leite-Moreira AF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today 2012; 17: 880-9.

7. Silva TE, Colombo G, Schiavon LL. Adiponectin: A multitasking player in the field of liver diseases. Diabetes Metab 2014; 40: 95-107.

8. Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-E89.

9. Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) 2010; 119: 431-6.

10. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-6.

11. Senates E, Colak Y, Yesil A, Coskunpinar E, Sahin O, Kahraman OT, Erkalma Senates B, et al. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores. Minerva Med 2012; 103: 369-76.

12. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008; 43: 1128-36.

13. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, De- Franco R, Mazzinghi B, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006; 169: 2042-53.

14. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006; 101: 1244-52.

15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.

16. Centers for Disease C, Prevention. Vital signs: current cigarette smoking among adults aged ≥ 18 years with mental illness - United States, 2009-2011. MMWR Morb Mortal Wkly Rep 2013; 62: 81-7.

17. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-53.

18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.

19. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

20. Morgan MY, Madden AM, Soulsby CT, Morris RW. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology 2006; 44: 823-35.

21. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr 1981; 34: 2540-5.

22. Tacke F, Wustefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, Trautwein C, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-73.

23. Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, Vogel W, Jaschke W, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005; 258: 274-80.

24. Nkontchou G, Bastard JP, Ziol M, Aout M, Cosson E, Ganne- Carrie N, Grando-Lemaire V, et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010; 53: 827-33.

25. Salman TA, Allam N, Azab GI, Shaarawy AA, Hassouna MM, El-Haddad OM. Study of adiponectin in chronic liver disease and cholestasis. Hepatol Int 2010; 4: 767-74.

26. Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, Rodriguez R, et al. Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology 2015; 88: 57-68.

27. Hamdy K, Al Swaff R, Hussein HA, Gamal M. Assessment of serum adiponectin in Egyptian patients with HCV-related cirrhosis and hepatocellular carcinoma. J Endocrinol Invest 2015; 38: 1225-31.

28. Kalafateli M, Triantos C, Tsochatzis E, Michalaki M, Koutroumpakis E, Thomopoulos K, Kyriazopoulou V, et al. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol 2015; 21: 3020-9.

29. Bahr MJ, Ockenga J, Boker KH, Manns MP, Tietge UJ. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E199-E206.

30. Kakizaki S, Sohara N, Yamazaki Y, Horiguchi N, Kanda D, Kabeya K, Katakai K, et al. Elevated plasma resistin concentrations in patients with liver cirrhosis. J Gastroenterol Hepatol 2008; 23: 73-7.

31. Latif HA, Assal HS, Mahmoud M, Rasheed WI. Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus. Clin Exp Med 2011; 11: 123-9.

32. Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int 2005; 25: 28-32.

33. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166: 1655-69.

34. Hutcheson J. Adipokines influence the inflammatory balance in autoimmunity. Cytokine 2015; 75: 272-9.

35. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014; 61: 1385-96.

36. Lopez-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, Fernandez-Real JM. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004; 60: 256-63.

37. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-51.

38. Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. Obes Rev 2013; 14: 939-49.

39. Martinez EC FM, Anjos LA. Influencia do estado nutricional e do VO2max nos níveis de adiponectina em homens acima de 35 anos. Arq Bras Cardiol 2011; 96: 471-6.

40. Greco AV, Mingrone G, Favuzzi A, Capristo E, Gniuli D, Addolorato G, Brunani A, et al. Serum leptin levels in posthepatitis liver cirrhosis. J Hepatol 2000; 33: 38-42.

41. Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol 1989; 8: 107-14.

42. Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, et al. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur J Clin Invest 2011; 41: 898-905.

43. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-504.

44. Siagris D, Vafiadis G, Michalaki M, Lekkou A, Starakis I, Makri M, Margaritis V, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007; 14: 577-83.

45. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145: 367-83.

46. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.

47. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54: 795-802.

48. Jiang LL, Li L, Hong XF, Li YM, Zhang BL. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol 2009; 21: 662-6.

49. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 2005; 42: 568-77.

50. Rogers CQ, Ajmo JM, You M. Adiponectin and alcoholic fatty liver disease. IUBMB Life 2008; 60: 790-7.

51. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.

52. You M, Rogers CQ. Adiponectin: a key adipokine in alcoholic fatty liver. Exp Biol Med (Maywood) 2009; 234: 850-9.

53. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165: 622-32.

54. Gnacinska M, Malgorzewicz S, Stojek M, Lysiak-Szydlowska W, Sworczak K. Role of adipokines in complications related to obesity: a review. Adv Med Sci 2009; 54: 150-7.

55. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009; 133: 157-70.

56. Singh AK, Tiwari S, Gupta A, Natu SM, Mittal B, Pant AB. Association of resistin with metabolic syndrome in Indian subjects. Metab Syndr Relat Disord 2012; 10: 286-91.

57. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz Wika J, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 2008; 57: 488-93.

58. Morace C, Spadaro A, Cucunato M, Tortorella V, Consolo P, Luigiano C, Stabile G, et al. High serum resistin in chronic viral hepatitis is not a marker of metabolic disorder. Hepatogastroenterology 2010; 57: 1215-9.

59. Shen C, Zhao CY, Wang W, Wang YD, Sun H, Cao W, Yu WY, et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol 2014; 14: 39.

60. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-26.

61. Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, Isenovic ER. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des 2014; 20: 4961-9.

62. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-9.

63. Lee SE, Kim HS. Human resistin in cardiovascular disease. J Smooth Muscle Res 2012; 48: 27-35.

64. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286-90.

65. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005; 29: 1315-20.

66. Watt KD, Fan C, Therneau T, Heimbach JK, Seaberg EC, Charlton MR. Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl 2014; 20: 791-7.

67. Nakagawa H, Fujiwara N, Tateishi R, Arano T, Nakagomi R, Kondo M, Minami T, et al. Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients. J Gastroenterol Hepatol 2015; 30: 379-88.